Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.

Schaefer, Franz; Ardissino, Gianluigi; Ariceta, Gema; Fakhouri, Fadi; Scully, Marie; Isbel, Nicole; Lommelé, Åsa; Kupelian, Varant; Gasteyger, Christoph; Greenbaum, Larry A; Johnson, Sally; Ogawa, Masayo; Licht, Christoph; Vande Walle, Johan; Frémeaux-Bacchi, Véronique.
Kidney Int; 94(2): 408-418, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29907460
Atypical hemolytic uremic syndrome (aHUS) is a rare, genetic, life-threatening disease. The Global aHUS Registry collects real-world data on the natural history of the disease. Here we characterize end-stage renal disease (ESRD)-free survival, the rate of thrombotic microangiopathy, organ involvement and the genetic background of 851 patients in the registry, prior to eculizumab treatment. A sex-specific difference was apparent according to age at initial disease onset as the ratio of males to females was 1.3:1 for childhood presentation and 1:2 for adult presentation. Complement Factor I and Membrane Cofactor Protein mutations were more common in patients with initial presentation as adults and children, respectively. Initial presentation in childhood significantly predicted ESRD risk (adjusted hazard ratio 0.55 [95% confidence interval 0.41-0.73], whereas sex, race, family history of aHUS, and time from initial presentation to diagnosis, did not. Patients with a Complement Factor H mutation had reduced ESRD-free survival, whereas Membrane Cofactor Protein mutation was associated with longer ESRD-free survival. Additionally extrarenal organ manifestations occur in 19%-38% of patients within six months of initial disease presentation (dependent on organ). Thus, our real-world results provide novel insights regarding phenotypic variables and genotypes on the clinical manifestation and progression of aHUS.
Selo DaSilva